L. Millheiser
YOU?
Author Swipe
View article: The association of race, ethnicity, and socioeconomic status on the severity of menopause symptoms: a study of 68,864 women
The association of race, ethnicity, and socioeconomic status on the severity of menopause symptoms: a study of 68,864 women Open
Objective This study aimed to evaluate if and how race, ethnicity, and socioeconomic status (SES) are associated with the severity of menopause symptoms in a large, diverse sample of women. Methods For this cross-sectional study conducted …
View article: The Impact of Race, Ethnicity, and Socioeconomic Status on the Severity of Menopause Symptoms: A Study of 68,864 Women
The Impact of Race, Ethnicity, and Socioeconomic Status on the Severity of Menopause Symptoms: A Study of 68,864 Women Open
Objective To evaluate how race, ethnicity, and socioeconomic status (SES) affect the severity of menopause symptoms in a large, diverse sample of women. Methods For this cross-sectional study conducted between March 24, 2019, and January 1…
View article: Effects of Alcohol Administered with Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study
Effects of Alcohol Administered with Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study Open
Introduction Flibanserin is approved in the United States and Canada for the treatment of hypoactive sexual desire disorder in premenopausal women. Aim The purpose of this trial was to evaluate the safety of concomitant administration of f…
View article: Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects
Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects Open
Introduction Flibanserin, a treatment for hypoactive sexual desire disorder, carries warnings for increased risk of severe hypotension and syncope when used with alcohol. However, these warnings are not informed by studies that used fliban…
View article: Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia
Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia Open
Objective: The softgel 17β-estradiol (E2) vaginal inserts (4 and 10 μg; Imvexxy; TherapeuticsMD, Boca Raton, FL) are FDA approved for treating moderate to severe dyspareunia associated with postmenopausal vulvar and vaginal atrophy (VVA). …
View article: Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials
Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials Open
Background: Flibanserin, a 5-hydroxytryptamine 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis assessed p…